Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries

Trial Profile

Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms DESSOLVE III
  • Most Recent Events

    • 22 Mar 2016 According to a Micell Technologies media release, enrollment of 60 patients in the optical coherence tomography sub-study has been completed.
    • 09 Dec 2015 Planned end date changed from 1 Oct 2018 to 1 Dec 2018, as reported by ClinicalTrials.gov.
    • 09 Dec 2015 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top